CFTR Modulators Restore Acidification of Autophago-Lysosomes and Bacterial Clearance in Cystic Fibrosis Macrophages

Asmaa Badr1,2, Mostafa Eltobgy1, Kathrin Krause1,3

  • 1Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH, United States.

Insights

Cystic fibrosis (CF) macrophages struggle to clear bacteria due to halted autophagy. CFTR modulators restore lysosomal function and bacterial clearance by improving CFTR activity in autophagosomes.

Area of Science:

  • Cell Biology
  • Immunology
  • Genetics

Background:

  • Cystic fibrosis (CF) macrophages exhibit impaired bacterial clearance, particularly of Burkholderia cenocepacia.
  • The autophagy pathway is defective in CF (F508del) macrophages, with the precise mechanism remaining elusive.
  • The role of the cystic fibrosis transmembrane conductance regulator (CFTR) in lysosomal and endosomal acidification in CF cells is debated.

Purpose of the Study:

  • To investigate the role of CFTR in the autophagy pathway and lysosomal acidification in CF macrophages.
  • To determine if CFTR modulators can restore autophagic function and bacterial clearance in CF macrophages.

Main Methods:

  • 3D reconstruction of z-stack confocal images to visualize CFTR recruitment to autophagosomes.
  • Complementary biochemical and imaging approaches to assess lysosomal acidification and degradative function.
  • Patch-clamp electrophysiology to confirm CFTR function after modulator treatment.

Main Results:

  • CFTR was observed to be recruited to autophagosomes containing B. cenocepacia.
  • CF macrophages showed defective lysosomal acidification and cargo degradation specifically for autophagosomal contents.
  • Treatment with CFTR modulators (tezacaftor/ivacaftor) restored autophagy flux, lysosomal acidification, bacterial clearance, and CFTR function.

Conclusions:

  • CFTR regulates the acidification of a specific subset of lysosomes involved in autophagosome fusion.
  • This study identifies a novel role for CFTR in autophagolysosomes, clarifying previous discrepancies in CF research.
  • CFTR modulators hold therapeutic potential for restoring macrophage function in cystic fibrosis.

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
232
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
384
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.0K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
359